Posted on:Weil in the News
Weil’s Munich and Paris offices are advising Santé Cie SAS, which is majority-owned by Ardian, on the acquisition of a majority stake in Aposan, a leading German pharmaceutical homecare provider from IK Small Cap I Fund, which is advised by IK Investment Partners.
Founded in 1991, Aposan is a specialized homecare provider in the field of outpatient parenteral antibiotic therapy, one of the fastest growing segments in the German home care market, as well as parenteral & enteral nutrition and ophthalmic injectables, covering the full homecare value chain from pharmaceutical compounding to care delivery. Aposan is headquartered in Cologne, Germany, and serves over 15,000 patients per year.
Created in 2016, Santé Cie is the third largest home healthcare provider in France, through its two operating networks Elivie and Asdia. The company supports over 160,000 homecare patients in France, covering a wide range of therapeutic segments including perfusion, nutrition, insulin therapy, the treatment of Parkinson’s disease, respiratory assistance and wound treatment and healing. Santé Cie has over 1,700 employees across 80 agencies throughout France, through its Elivie and Asdia networks.
The Weil team was led by Corporate partner Barbara Jagersberger and included Tax counsel Benjamin Rapp as well as Corporate associates Florian Wessel and Cornelia Tu; Finance associate Alexander Wandt; IP/Data Protection associate Barbara Sandfuchs; Tax associate Bao-Ngoc Nguyen; Employment Litigation associate Mareike Pfeiffer; Antitrust associate Steffen Giolda; and Corporate associates Côme Wirz and Maximilien Roland.